Syndax Pharmaceuticals, Inc. Debt Conversion, Converted Instrument, Amount
Syndax Pharmaceuticals, Inc. (SNDX) reported Debt Conversion, Converted Instrument, Amount of $5.21 million for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2018-03-08
- Syndax Pharmaceuticals, Inc. debt conversion, converted instrument, amount for the quarter ending 2015-12-31 was $0.00.
- Syndax Pharmaceuticals, Inc. debt conversion, converted instrument, amount for the quarter ending 2015-09-30 was $0.00.
- Syndax Pharmaceuticals, Inc. debt conversion, converted instrument, amount for fiscal 2015 was $5.21M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $0.00 derived: sum of 2 quarters · filed 2018-03-08 | $5.21M 10-K · filed 2018-03-08 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $5.21M 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | $5.21M 10-Q · filed 2016-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |